2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

• Published in: Journal of the American College of Cardiology Vol. 79; no. 17; pp. 1757 - 1780
• Main Authors: Heidenreich, Paul A., Bozkurt, Biykem, Aguilar, David, Allen, Larry A., Byun, Joni J., Colvin, Monica M., Deswal, Anita, Drazner, Mark H., Dunlay, Shannon M., Evers, Linda R., Fang, James C., Fedson, Savitri E., Fonarow, Gregg C., Hayek, Salim S., Hernandez, Adrian F., Khazanie, Prateeti, Kittleson, Michelle M., Lee, Christopher S., Link, Mark S., Milano, Carmelo A., Nnacheta, Lorraine C., Sandhu, Alexander T., Stevenson, Lynne Warner, Vardeny, Orly, Vest, Amanda R., Yancy, Clyde W.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 03.05.2022
• Subjects: ACC/AHA Clinical Practice Guidelines; ACE inhibitors; acute decompensated heart failure; angiotensin and neprilysin receptor antagonist; angiotensin receptor antagonist; atrial fibrillation; beta blockers; cardiac amyloidosis; cardiac failure; cardio-oncology; cardiogenic shock; cardiomyopathy; cardiomyopathy in pregnancy; Cardiovascular; chronic heart failure; congestive heart failure; diabetes; guideline-directed medical therapy; heart failure; heart failure rehabilitation; heart failure with mildly reduced ejection fraction; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; Internal Medicine; mineralocorticoid receptor antagonists; mitral regurgitation; palliative care; reduced ejection fraction; right heart pressure; sacubitrilvalsartan; SGLT2 inhibitors; social determinants of health; sodium glucose co-transporter 2; systolic heart failure; valvular heart disease; ACC/AHA Clinical Practice Guidelines; right heart pressure; angiotensin receptor antagonist; chronic heart failure; cardiogenic shock; beta blockers; palliative care; reduced ejection fraction; atrial fibrillation; heart failure with preserved ejection fraction; heart failure with mildly reduced ejection fraction; congestive heart failure; valvular heart disease; mineralocorticoid receptor antagonists; sacubitrilvalsartan; cardiomyopathy; heart failure with reduced ejection fraction; SGLT2 inhibitors; heart failure; social determinants of health; mitral regurgitation; systolic heart failure; acute decompensated heart failure; cardio-oncology; guideline-directed medical therapy; angiotensin and neprilysin receptor antagonist; cardiomyopathy in pregnancy; heart failure rehabilitation; cardiac amyloidosis; sodium glucose co-transporter 2; ACE inhibitors; diabetes; cardiac failure

The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.” The 2022 guideline is intended to provide pa...